Abstracts tagged "Disease Activity"

Abstract Number: 2285 • 2015 ACR/ARHP Annual Meeting
Poor Quality of Sleep Is Associated with Increased Disease Activity and Fatigue in Axial Spondyloarthritis
Lana Frost¹, Jiayi Zhou², Lourdes Pena Castillo², Sean Hamilton¹, Nayef Al Ghanim¹, Proton Rahman¹ and Jennifer Burt¹, ¹Rheumatology, St. Clare's Mercy Hospital, St. John's, NF, Canada, ²Computer Science, Memorial University of Newfoundland, St. John's, NF, Canada
Background/Purpose: Sleep disturbance is a common occurrence in musculoskeletal disease including ankylosing spondylitis. The reasons for the sleep disturbance in rheumatic diseases are multifactorial. There…
Abstract Number: 2601 • 2015 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score in a TNF Inhibitor Tapering Study in Rheumatoid Arthritis Patients: Predictive Value for Successful Tapering, Flaring and Radiographic Progression
Chantal A.M. Bouman¹, Aatke van der Maas¹, Noortje van Herwaarden¹, Eric H. Sasso², Frank H.J. van den Hoogen¹ and Alfons A. den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: We evaluated the predictive value of the multi-biomarker disease activity (MBDA) score for clinical outcomes and radiographic progression in a TNFi tapering study in…
Abstract Number: 2682 • 2015 ACR/ARHP Annual Meeting
A Brief Patient-Reported Measure of Physical Function Is Sensitive to Changes in a Composite Disease Activity Measure in a Diverse Rheumatoid Arthritis Clinic Setting
Elizabeth R. Wahl^1,2, Andrew Gross², Vladimir Chernitskiy², Laura Trupin², Jinoos Yazdany³ and Patricia P. Katz², ¹Medicine/Rheumatology, San Francisco Veterans Affairs Medical Center, San Francisco, CA, ²Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) patients' physical function is a strong predictor of clinical outcomes. A brief patient-reported measure of physical function, the PROMIS PF-10a (PF-10a),…
Abstract Number: 3118 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Disease Outcomes in Psoriatic Arthritis Patients By Extent of Body Surface Area Affected By Psoriasis: Results from Corrona Registry
Philip J. Mease^1,2,3,4, Chitra Karki⁵, Carol J. Etzel^5,6, Arthur Kavanaugh⁷, Christopher T. Ritchlin⁸, Wendi Malley⁵, Vivian Herrera⁹, Jacqueline B. Palmer⁹ and Jeffrey D. Greenberg^5,10, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Seattle Rheumatology Associates, Seattle, WA, ³Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁴Clinical Professor, University of Washington School of Medicine, Seattle, WA, ⁵Corrona, LLC, Southborough, MA, ⁶University of Texas M.D. Anderson Cancer Center, Houston, TX, ⁷University of California San Diego, La Jolla, CA, ⁸Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰NYU School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a type of inflammatory arthritis that is commonly comorbid with the skin condition, psoriasis. A major contributor to the severity…
Abstract Number: 217 • 2015 ACR/ARHP Annual Meeting
Circulating Levels of Neo-Epitopes Reflecting Connective Tissue Turnover As Biomarkers of Gout and Frequent Gout Attacks in Men
Ana Valdes¹, Tina Manon-Jensen², Wendy Jenkins³, Anne Sofie Siebuhr⁴, Morten Asser Karsdal⁴, Sally Doherty⁵, Abhishek Abhishek³, Helen Richardson³, Weiya Zhang⁶, Michael Doherty⁷ and Anne C. Bay-Jensen⁸, ¹Division of Rheumatology, Orthopaedics and Dermatology, University of Nottingham, Nottingham, United Kingdom, ²Antibody Research Unit, Nordic Bioscience, 2370, Denmark, ³Devision of Rheumatology, University of Nottingham, NG5 1PB, England, ⁴Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁵Division of ROD, University of Nottingham, Nottingham, United Kingdom, ⁶Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ⁷Academic Rheumatology, City Hospital, Nottingham, United Kingdom, ⁸Biomarkers and Research, Rheumatology, Nordic Bioscience, Herlev, Denmark
Background/Purpose: Recurrent flares constitute the main clinical burden of gout. The neo-epitope blood-based biomarkers, C1M and C3M, measuring matrix metalloproteinases (MMP)-mediated connective tissue degradation, have previously…
Abstract Number: 561 • 2015 ACR/ARHP Annual Meeting
Improvement in Disease Activity and the Long-Term Risk of Serious Infectious Events in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
Jeffrey R. Curtis¹, Marc de Longueville², Cathy O'Brien² and Boulos Haraoui³, ¹University of Alabama at Birmingham, Birmingham, AL, ²UCB Pharma, Brussels, Belgium, ³Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
Background/Purpose: Anti-TNF drugs are an effective treatment option for rheumatoid arthritis (RA) patients (pts) but have been associated with an increased incidence of serious infectious…
Abstract Number: 785 • 2015 ACR/ARHP Annual Meeting
Further Validation of Simple Index As a Simple Disease Activity Assessment Tool for SLE
Nisarg Gandhi¹, Meenakshi Jolly², Alana Nevares³ and Winston Sequeira¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL, ³Internal Medicine, Cook County Hospital, Chicago, IL
Background/Purpose: An easy, quick tool, requiring minimal training or physician input for disease activity (DA) assessment in SLE, would have potentially greater uptake for routine…
Abstract Number: 1620 • 2015 ACR/ARHP Annual Meeting
DNA Methylation Profiling of Rheumatoid Arthritis Peripheral Blood Identifies Hypermethylation of TRIM69 Promoter Region in CD4+ T Cells Associated with Disease Activity
Amanda Mok¹, Brooke Rhead¹, Calliope Holingue¹, Xiaorong Shao¹, Diana Quach¹, Hong L. Quach¹, Elizabeth Sinclair², Jonathan D. Graf³, Thomas M. Link⁴, Ruby Harrison³, Vladimir Chernitskiy³, Wei Wang⁵, Gary S. Firestein⁶, Lisa F. Barcellos¹ and Lindsey A. Criswell³, ¹Genetic Epidemiology and Genomics Laboratory, University of California, Berkeley, Berkeley, CA, ²Division of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, ³Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA, ⁴Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA, ⁵Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, ⁶Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA
Background/Purpose: Epigenetic modifications have been previously associated with rheumatoid arthritis (RA [MIM 180300]). This study aimed to determine whether differential DNA methylation in peripheral blood…
Abstract Number: 2317 • 2015 ACR/ARHP Annual Meeting
Different Rheumatoid Arthritis Disease Activity Measures Often Provide Discordant Results in Clinical Practice Populations
Gary Crump¹, James Bower², Terrence Foley³, J. Timothy Harrington², Nikita Hegde⁴, Drew Johnson⁵, Rafia Khalil⁶, Edmund LaCour⁷ and Robert Perhala⁸, ¹Rheumatology Associates - Louisville, Louisville, KY, ²Joiner Associates LLC, Madison, WI, ³Terrence Foley MD Inc, Concord Twp, OH, ⁴Akron General Hospital, Cuyahoga Falls, OH, ⁵Crescendo Bioscience, Inc., South San Francisco, CA, ⁶Rafia Khalil Arthritis & Rheumatology Center, PC, Port Huron, MI, ⁷Dothan Medical Associates PC, Dothan, AL, ⁸University Hospitals, Cleveland, OH
Background/Purpose: Accurate rheumatoid arthritis (RA) disease activity assessment is required for treatment consistent with Treat-to-Target (T2T) recommendations. Rheumatologists currently use a variety of patient-generated, physician-generated,…
Abstract Number: 2604 • 2015 ACR/ARHP Annual Meeting
Evaluation of Serum Undercarboxylated Osteocalcin in Premenopausal Rheumatoid Arthritis Patients; Its Correlation with Disease Activity and Bone Mineral Density
Heba Esaily¹, Abd El Samad Al Hewala², Samar Soliman³, Eman Galbat⁴ and Dalia Abo Al- Ela⁵, ¹Physical Medicine and Rehabilitation,, Faculty of Medicine, Menoufia University, Menofia, Egypt, ²Department of Rheumatology, Faculty of Medecine, Zagazigue University, Al Sharquia, Egypt, ³Physical Medicine and Rehabilitation, Faculty of Medicine, Menoufia University, Menoufia,, Egypt, ⁴Physical Medicine and Rehabilitation, Faculty of Medicine, Menoufia University, Menoufia, Egypt, ⁵Clinical Pathology, Faculty of Medicine, Menoufia University, Menofia, Egypt
Background/Purpose: The role of vitamin K and undercarboxylated osteocalcin (ucOC) on BMD in RA is present. Up to our knowledge no other works have discussed…
Abstract Number: 2683 • 2015 ACR/ARHP Annual Meeting
Contribution of Subjective Patient Reported Components of Disease Activity Scores Differs in Disease Activity Measures and Their Changes over Time Are Closely Associated with Objective Measures
Yong Gil Hwang¹, Juan (June) Feng², Heather Eng², Jason Lyons², Anthony Fabio³ and Larry W. Moreland⁴, ¹Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ³Department Of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Patient reported measures are influenced by many non-rheumatoid arthritis (RA) factors and they are reflected variably among various composite disease activity scores (DAS). We…
Abstract Number: 3147 • 2015 ACR/ARHP Annual Meeting
Inter-Provider Reliability in Scoring the Physician Global Assessment of Disease Activity Among Patients with Juvenile Idiopathic Arthritis Patients Who Met the ACR Provisional Criteria for Clinical Inactive Disease
Janalee Taylor¹, Edward H. Giannini¹, Daniel Lovell² and Esi M. Morgan DeWitt¹, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: With the advent and implementation of advanced drug therapy clinical inactive disease (CID) has become an attainable target in the treatment of juvenile idiopathic…
Abstract Number: 267 • 2015 ACR/ARHP Annual Meeting
Association of CXCL10 and CXCL13 Levels with Disease Activity and Cutaneous Manifestation in Active Adult-Onset Still’s Disease
Hyoun-Ah Kim¹, In Je Kim², Jae Ho Han³, Chang-Hee Suh¹ and Juyang Jung¹, ¹Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, South Korea, ³Department of Pathology, Ajou University School of Medicine, Suwon, South Korea
Background/Purpose: CXCL10 is produced in response to interferon-γ, and tumor necrosis factor-α (TNF-α) triggers the accumulation of activated lymphocytes. CXCL13 is constitutively expressed in secondary…
Abstract Number: 576 • 2015 ACR/ARHP Annual Meeting
Possibility of Extension of the Administration Interval of Tocilizumab in the Treatment of Rheumatoid Arthritis
Masao Sato¹ and Masao Takemura², ¹Rheumatology, Matsunami General Hospital, Gifu, Japan, ²Matsunami Reserch Park, Gifu, Japan
Background/Purpose: Biologics constitute an important drug category in the pharmacological treatment of rheumatoid arthritis (RA). Drug-free remission (REM) may also be achievable if the condition…
Abstract Number: 867 • 2015 ACR/ARHP Annual Meeting
Simultaneous Measurement of 25-Hydroxyvitamin D and Procalcitonin in Granulomatosis with Polyangiitis (GPA): Differentiation of Activity from Infection?
Mariana O Perez¹, Ricardo M. Oliveira², Valéria Caparbo^3,4, Mauricio Levy-Neto⁵, Eloisa Bonfá⁴ and Rosa M R Pereira³, ¹Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²RDO Diagnósticos Médicos, São Paulo, Brazil, ³Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology DIvision, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Vitamin D acts as innate and adaptive immune response immunomodulator. 25-hydroxyvitamin D (25OHD) deficiency was reported to be associated with autoimmune diseases flares and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].